Travis Cook, M.S., M.B.A. (OHSU)
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging-2
Researchers with OHSU’s Neuro-Oncology Blood-Brain Barrier Program supported several clinical trials investigating a novel use of a drug for brain cancer imaging; the data helped achieve its recent FDA-approval. (OHSU/Christine Torres Hicks)
Laszlo Szidonya, M.D., Ph.D. (OHSU)
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging 3
From left: Amy Huddleston, Lisa Muir, Rochelle Fu, Ramon Barajas, Leslie Muldoon, and Laszlo Szidonya. (OHSU/Christine Torres Hicks)
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging 2
Researchers with OHSU’s Neuro-Oncology Blood-Brain Barrier Program supported several clinical trials investigating a novel use of a drug for brain cancer imaging; the data helped achieve its recent FDA-approval. (OHSU/Christine Torres Hicks)
Leslie Muldoon, Ph.D. (OHSU)
Lisa Muir, M.P.A., H.A., C.C.R.P. (OHSU)
Project seeks to develop retinal screening for Alzheimer’s
OHSU scientist Lei Wang, Ph.D., is part of a new federally funded initiative to develop an eye scan to detect early screening for Alzheimer’s disease. Wang, an organic chemist by training, is collaborating with OHSU imaging expert Yifan Jian, Ph.D. If the research initiative succeeds, it could result in a low-cost and widely accessible screening tool. (OHSU/Erik Robinson)
Yifan Jian, Ph.D. (OHSU)
